The accelerated FDA approval of Bayer's Hyrnuo covers treatment of advanced cases of non-small cell lung cancer with HER2 mutations. It will compete against an HER2-targeting Boehringer Ingelheim pill ...
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer.
By Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for ...
The FDA has given accelerated approval to Bayer for oral HER2 tyrosine kinase inhibitor sevabertinib as a second-line ...
WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., July 25, 2014 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an ...
Bayer and SBM Développement (SBM) today announced the signing of an agreement for the sale of the Consumer business of Bayer’s Environmental Science unit to SBM. The Consumer business encompasses the ...
By Sriparna Roy (Reuters) -The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer that has advanced or spread despite previous ...
(Reuters) -The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer that has advanced or spread despite previous treatments. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback